SUBSEQUENT EVENTS	6 Months Ended
Jun. 30, 2025
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 6 – SUBSEQUENT EVENTS During the period July 1, 2025 to August 8, 2025, the Company raised approximately $13,275 in gross proceeds from the exercise of an aggregate of 7,697,623 outstanding Series G and F preferred investment options. In connection with these exercises, the Company issued 7,487,623 shares, while 210,000 shares were pending issuance as of August 8, 2025. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company is obligated to pay a cash fee of approximately $929 to its placement agent and to issue an aggregate of 384,881 placement agent options. On July 1, 2025, the Company issued 100,000 shares of common stock in connection with the exercise of a preferred investment option on June 30, 2025. In July 2025 the IIA approved a new grant in the amount of approximately NIS 2.2 million (approximately $630,000) to further finance the development of the manufacturing process of the LIBERTY^® Endovascular Robotic Surgical System. The One Big Beautiful Bill Act (“OBBBA”) was enacted on July 4, 2025, extending key provisions of 2017 Tax Act. The Company continues to evaluate the impact on its financial position. The OBBBA is not currently expected to have a material impact on the Company’s results of operations.

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2025

NOTE 6 – SUBSEQUENT EVENTS

During the period July 1, 2025 to August 8, 2025, the Company raised approximately $13,275 in gross proceeds from the exercise of an aggregate of 7,697,623 outstanding Series G and F preferred investment options. In connection with these exercises, the Company issued 7,487,623 shares, while 210,000 shares were pending issuance as of August 8, 2025. As a result of these exercises, and in accordance with the Company’s engagement letters with its placement agent, as mentioned in Note 3D, the Company is obligated to pay a cash fee of approximately $929 to its placement agent and to issue an aggregate of 384,881 placement agent options.

On July 1, 2025, the Company issued 100,000 shares of common stock in connection with the exercise of a preferred investment option on June 30, 2025.

In July 2025 the IIA approved a new grant in the amount of approximately NIS 2.2 million (approximately $630,000) to further finance the development of the manufacturing process of the LIBERTY^® Endovascular Robotic Surgical System.

The One Big Beautiful Bill Act (“OBBBA”) was enacted on July 4, 2025, extending key provisions of 2017 Tax Act. The Company continues to evaluate the impact on its financial position. The OBBBA is not currently expected to have a material impact on the Company’s results of operations.